Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIN-2787 in BRAF/NRAS-mutated Solid Tumors
NCT04913285Phase 1Recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Aug 2021
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of exarafenib in solid tumor, non-small cell lung cancer (NSCLC) and melanoma (4 arms), sponsored by Pierre Fabre Laboratories. Primary endpoints: Safety and Tolerability up to 18 months, Objective Response Rate up to 36 months and 3 more. Started Aug 2021; status: recruiting.
02
Drugs
exarafenib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT04913285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913285.